Provided by Tiger Trade Technology Pte. Ltd.

Anixa Biosciences

2.82
+0.07002.55%
Volume:141.54K
Turnover:401.83K
Market Cap:98.03M
PE:-9.29
High:2.88
Open:2.87
Low:2.80
Close:2.75
52wk High:5.46
52wk Low:2.32
Shares:34.76M
Float Shares:32.61M
Volume Ratio:0.61
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3035
EPS(LYR):-0.3367
ROE:-73.17%
ROA:-41.93%
PB:6.77
PE(LYR):-8.38

Loading ...

Top News Today/Canada: Kneat.com to be Acquired by Thoma Bravo

Dow Jones
·
Jun 09

Anixa Biosciences: CIPO issues Notice of Allowance for patent

TIPRANKS
·
Jun 01

Anixa Biosciences Says Canadian IP Office Issues Notice of Allowance for Patent Covering Ovarian Cancer Vaccine Technology

MT Newswires Live
·
Jun 01

Anixa Biosciences - Receives Canadian Notice of Allowance for Ovarian Cancer Vaccine Patent

THOMSON REUTERS
·
Jun 01

Anixa Biosciences says Canada issues notice of allowance for ovarian cancer vaccine patent

Reuters
·
Jun 01

North American Morning Briefing: Oil Rises After Fresh Attacks on Iran

Dow Jones
·
May 26

Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
May 23

Anixa reports updated survival data from Phase 1 lira-cel ovarian cancer CAR-T trial

Reuters
·
May 11

Anixa Biosciences Inc - No Dose-Limiting Toxicities, Icans, or Significant Crs Observed in First Three Dose Cohorts

THOMSON REUTERS
·
May 11

Anixa Biosciences Reports Updated Positive Survival Observations From Ongoing Phase 1 Trial of Lira-Cel Ovarian Cancer CAR-T Therapy

THOMSON REUTERS
·
May 11

Anixa Biosciences wins Mexican patent for breast cancer vaccine technology

Reuters
·
Apr 29

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology

THOMSON REUTERS
·
Apr 29

Anixa to present ovarian cancer CAR-T trial update at ISCT annual meeting

Reuters
·
Apr 22

Anixa CEO presents at RedChip Biotech Resurgence virtual investor conference

Reuters
·
Apr 09

Anixa Biosciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 08

Anixa CEO cites positive Phase 1 data for breast cancer vaccine, ovarian CAR-T in interview

Reuters
·
Apr 06

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences

Reuters
·
Apr 02

Anixa Biosciences announces agreement with Cytovance Biologics

TIPRANKS
·
Apr 01

Anixa advances breast cancer vaccine toward Phase 2 after positive Phase 1 data

Reuters
·
Apr 01

Anixa Biosciences Inc: Phase 1 Study Met Primary Endpoints, Showed Safety and Tolerability at Maximum Tolerated Dose

THOMSON REUTERS
·
Apr 01